サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1529695

帯状疱疹ワクチンの市場規模、シェア、動向分析レポート：製品別、タイプ別、最終用途別、地域別、セグメント別予測、2024年～2030年

Shingles Vaccine Market Size, Share & Trends Analysis Report By Product (Shingrix, Zostavax), By Type (Recombinant Vaccine), By End-use (Private Healthcare Settings), By Region, And Segment Forecasts, 2024 - 2030

出版日
ページ情報
英文 90 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
帯状疱疹ワクチンの市場規模、シェア、動向分析レポート：製品別、タイプ別、最終用途別、地域別、セグメント別予測、2024年～2030年
出版日: 2024年07月08日
発行: Grand View Research
ページ情報: 英文 90 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

帯状疱疹ワクチン市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の帯状疱疹ワクチン市場規模は2030年までに112億6,000万米ドルに達し、予測期間中に15.34%のCAGRを記録する見込みです。

先進諸国における帯状疱疹の発症率の増加と帯状疱疹に関する高い認知度が市場拡大に寄与しています。CDCによると、米国では毎年100万件近くの帯状疱疹の症例が報告されています。さらに、同国では3人に1人が一生のうちに発症するとされています。

ワクチンの採用が増加し、さまざまな政府規制機関によるワクチン接種の推奨が増加していることが、予測期間にわたって市場を牽引すると予想されます。例えば、2019年2月、英国の予防接種合同委員会（JCVI）は、60～70歳の成人の帯状疱疹予防に組換えワクチンの使用を推奨しています。

数カ国の国家予防接種プログラムに帯状疱疹ワクチンが含まれることで、ワクチン需要が促進されると予想されます。例えば、英国では2013年から帯状疱疹ワクチンが国家予防接種プログラムの一部となっています。英国は欧州地域で初めて国家予防接種プログラムに帯状疱疹ワクチンを導入した国であり、ワクチン1回分の接種費用は国民保健サービス（NHS）で約130米ドルです。同様に、米国、イタリア、オーストラリア、カナダのいくつかの州、韓国などの他の国も予防接種プログラムにこのワクチンを組み込んでいます。

そのほか、新興国市場では、発症リスクのある人々の意識を高めるために、市場関係者や規制当局が積極的な取り組みを行っており、今後数年間の市場成長を後押しすると期待されています。例えば、GlaxoSmithKline plc.は、予防接種に関連する利点について人々を教育することにより、高齢者の予防接種率を高めるキャンペーンを開始しました。

ワクチンの高い有効性により、予測期間中の普及が期待されます。臨床試験結果によると、Shingrixは帯状疱疹および帯状疱疹後神経痛の予防に非常に有効です。Shingrixの2回投与は、50歳以上の成人において90％以上の予防効果があります。接種後少なくとも4年間は85％以上の予防効果が持続します。

ワクチンが低価格で入手可能であることに加え、先進諸国では罹患率が高く、ワクチン接種率も高いことから、市場の成長に拍車がかかると予想されます。英国、米国、フランス、カナダ、ドイツ、韓国の帯状疱疹に対するワクチン接種率は、他の国に比べて高いです。例えば、英国は帯状疱疹ワクチンの接種率が最も高く、対象となる成人の60%以上が接種を受けています。

帯状疱疹ワクチン市場レポートハイライト

  • 製品別では、シングリックスが2023年に最大のシェアを占めました。また、規制当局による帯状疱疹予防の推奨が増加していることから、Shingrixは予測期間中に大きなCAGRで成長する見込みです。
  • ワクチンの種類別では、組み換えワクチンに関連するリスクが低いことから、組み換えワクチン分野は予測期間中に大幅な成長が見込まれます。
  • アジア太平洋地域は、アンメットニーズが高く、ワクチン接種プログラムの導入が進んでいることから、予測期間中に最も急成長すると予測されます。
  • 北米は、有利な償還政策とヘルスケア専門家や患者の意識を高めるためのイニシアチブの高まりにより、2023年の市場を独占しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 帯状疱疹ワクチン市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場牽引要因分析
    • 市場抑制要因分析
  • 帯状疱疹ワクチン市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析
    • パイプライン分析

第4章 帯状疱疹ワクチン市場：製品別推定・動向分析

  • 世界の帯状疱疹ワクチン市場：製品別ダッシュボード
  • 世界の帯状疱疹ワクチン市場：製品別変動分析
  • 世界の帯状疱疹ワクチン市場：製品別収益
  • シングリックス
  • ゾスタバックス
  • スカイゾスター

第5章 帯状疱疹ワクチン市場：タイプ別推定・動向分析

  • 世界の帯状疱疹ワクチン市場：タイプ別ダッシュボード
  • 世界の帯状疱疹ワクチン市場：タイプ別変動分析
  • 世界の帯状疱疹ワクチン市場：タイプ別収益
  • 組み換えワクチン
  • 生弱毒化ワクチン

第6章 帯状疱疹ワクチン市場：最終用途別推定・動向分析

  • 世界の帯状疱疹ワクチン市場：最終用途別ダッシュボード
  • 世界の帯状疱疹ワクチン市場：最終用途別変動分析
  • 世界の帯状疱疹ワクチン市場：最終用途別収益
  • 民間ヘルスケア機関
  • 政府のヘルスケア現場

第7章 帯状疱疹ワクチン市場：製品、タイプ、最終用途別の地域別推定・動向分析

  • 地域ダッシュボード
  • 市場規模と予測動向分析、2018年から2030年
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第8章 競合情勢

  • 企業/競合の分類
  • ベンダー情勢
    • 主要販売代理店およびチャネル パートナーのリスト
    • 主要顧客
    • 主要企業の市場シェア分析、2023 年
    • GlaxoSmithKline plc.
    • Merck &Co., Inc.
    • SK chemicals
    • Green Cross Corp
    • Geneone Life Science
    • Vaccitech
    • CanSinoBIO
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Shingles vaccine market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 5 U.S. shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 6 U.S. shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 7 U.S. shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 8 Canada shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 9 Canada shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 10 Canada shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Mexico shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 12 Mexico shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 13 Mexico shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 14 Europe shingles vaccine market, by region, 2018 - 2030 (USD Million)
  • Table 15 Europe shingles vaccine market, byproduct, 2018 - 2030 (USD Million)
  • Table 16 Europe shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 17 Europe shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 18 Germany shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 19 Germany shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 20 Germany shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 21 UK shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 22 UK shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 23 UK shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 24 France shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 25 France shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 26 France shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 27 Italy shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 28 Italy shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 29 Italy shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 30 Spain shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 31 Spain shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 32 Spain shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 33 Denmark shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 34 Denmark shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 35 Denmark shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 36 Sweden shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 37 Sweden shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 38 Sweden shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 39 Norway shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 40 Norway shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 41 Norway shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific shingles vaccine market, by region, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 45 Aisa Pacific shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 46 China shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 47 China shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 48 China shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 49 Japan shingles vaccine market, byproduct, 2018 - 2030 (USD Million)
  • Table 50 Japan shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 51 Japan shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 52 India shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 53 India shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 54 India shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 55 South Korea shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 56 South Korea shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 57 South Korea shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 58 Australia shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 59 Australia shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 60 Australia shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 61 Thailand shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 62 Thailand shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 63 Thailand shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 64 Latin America shingles vaccine market, by region, 2018 - 2030 (USD Million)
  • Table 65 Latin America shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 66 Latin America shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 67 Latin America shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 68 Brazil shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 69 Brazil shingles vaccine market, by vaccine product, 2018 - 2030 (USD Million)
  • Table 70 Brazil shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 71 Argentina shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 72 Argentina shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 73 Argentina shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 74 MEA shingles vaccine market, by region, 2018 - 2030 (USD Million)
  • Table 75 MEA shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 76 MEA shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 77 MEA shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 78 South Africa shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 79 South Africa shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 80 South Africa shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 84 UAE shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 85 UAE shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 86 UAE shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 87 Kuwait shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 88 Kuwait shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 89 Kuwait shingles vaccine market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Shingles vaccine market: market outlook
  • Fig. 14 Shingles vaccine market competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Shingles vaccine market driver impact
  • Fig. 18 Shingles vaccine market restraint impact
  • Fig. 19 Shingles vaccine market: Product movement analysis
  • Fig. 20 Shingles vaccine market: Product outlook and key takeaways
  • Fig. 21 Shingrix market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Zostavax market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 SKYZoster market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Shingles vaccine market: Vaccine type movement analysis
  • Fig. 25 Shingles vaccine market: Vaccine type outlook and key takeaways
  • Fig. 26 Recombinant Vaccine market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Live Attenuated Vaccine market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Shingles vaccine market: End Use movement analysis
  • Fig. 29 Shingles vaccine market: End Use outlook and key takeaways
  • Fig. 30 Private Healthcare Settings market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Government Healthcare Settings market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Global Shingles vaccine market: Regional movement analysis
  • Fig. 33 Global Shingles vaccine market: Regional outlook and key takeaways
  • Fig. 34 Global Shingles vaccine market share and leading players
  • Fig. 35 North America, by country
  • Fig. 36 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. key country dynamics
  • Fig. 38 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Canada key country dynamics
  • Fig. 40 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Mexico key country dynamics
  • Fig. 42 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 UK key country dynamics
  • Fig. 45 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Germany key country dynamics
  • Fig. 47 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 France key country dynamics
  • Fig. 49 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Italy key country dynamics
  • Fig. 51 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Spain key country dynamics
  • Fig. 53 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Denmark key country dynamics
  • Fig. 55 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Sweden key country dynamics
  • Fig. 57 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Norway key country dynamics
  • Fig. 59 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 China key country dynamics
  • Fig. 62 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Japan key country dynamics
  • Fig. 64 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 India key country dynamics
  • Fig. 66 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Thailand key country dynamics
  • Fig. 68 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 South Korea key country dynamics
  • Fig. 70 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Australia key country dynamics
  • Fig. 72 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Brazil key country dynamics
  • Fig. 75 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Argentina key country dynamics
  • Fig. 77 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 South Africa key country dynamics
  • Fig. 80 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Saudi Arabia key country dynamics
  • Fig. 82 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 UAE key country dynamics
  • Fig. 84 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Kuwait key country dynamics
  • Fig. 86 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Market share of key market players- Shingles vaccine market
目次
Product Code: GVR-4-68039-638-0

Shingles Vaccine Market Growth & Trends:

The global shingles vaccine market size is expected to reach USD 11.26 billion by 2030, registering a CAGR of 15.34% during the forecast period, according to a new report by Grand View Research, Inc. Increasing incidence of shingles and high awareness regarding shingles in developed countries are contributing to the market growth. According to the CDC, nearly one million cases of shingles are reported each year in the United States. Furthermore, one out of three individuals in the country will develop the disease in their lifetime.

The increasing adoption of vaccines and an increase in the recommendation of vaccination by different government regulatory bodies are expected to drive the market over the forecast period. For instance, in February 2019, the U.K. Joint Committee of Vaccination and Immunization (JCVI) has recommended the use of the recombinant vaccine to prevent shingles in adults aged 60 to 70 years old.

The inclusion of shingles vaccines in national immunization programs of several countries is anticipated to propel the demand for vaccines. For instance, the shingles vaccine is a part of the national immunization program in the U.K. since 2013. The U.K. is the first country in the European region to introduce shingles vaccine in the national immunization program and it costs around USD 130 to the National Health Service (NHS) for each dose of the vaccine. Similarly, other countries such as the U.S., Italy, Australia, and some provinces of Canada and South Korea have also included the vaccine in their immunization program.

Besides, favorable initiatives undertaken by market players and regulatory bodies to increase the awareness among people who are at risk of developing the disease are expected to fuel the market growth over the coming years. For instance, GlaxoSmithKline plc. has launched a campaign to increase vaccination rates among older adults by educating people about the benefits associated with vaccination.

The high efficacy of vaccines is expected to increase the adoption over the forecast period. According to clinical trial results, Shingrix is highly efficient to prevent shingles and postherpetic neuralgia. Two doses of Shingrix are more than 90% effective to prevent the disease in adults aged 50 years and above. Protection stays above 85% for at least the first four years after getting vaccinated.

The availability of vaccines at lower prices, coupled with a high incidence of the disease and high vaccination rate in developed countries, is anticipated to fuel the market growth. The vaccination rate against shingles in the U.K., the U.S., France, Canada, Germany, and South Korea is higher compared to other countries owing to better reimbursement policies and high awareness levels regarding the disease and vaccines. For instance, the U.K. has the highest shingles vaccine uptake with more than 60% vaccination of eligible adults.

Shingles Vaccine Market Report Highlights:

  • By product, Shingrix held the largest share in 2023, owing to the high efficacy of the vaccine as compared to others. Shingrix is also expected to grow at a significant CAGR over the forecast period owing to the increasing recommendations by regulatory bodies to prevent shingles
  • Based on vaccine type, the recombinant vaccine segment is anticipated to grow at a substantial rate over the forecast period due to the low risk associated with recombinant vaccines
  • Asia Pacific is projected to witness the fastest growth during the forecast period owing to the high unmet needs and the rising adoption of vaccination programs in the region
  • North America dominated the market in 2023, due to favorable reimbursement policies and rising initiatives to raise awareness among healthcare professionals and patients.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Type
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Type outlook
    • 2.2.3. End Use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Shingles Vaccine Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing risk of developing shingles
      • 3.2.1.2. Increase in recommendation of shingles vaccine
      • 3.2.1.3. Cost - effectiveness of shingles vaccine
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Low awareness regarding shingles
      • 3.2.2.2. Weak product pipeline
  • 3.3. Shingles Vaccine Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis

Chapter 4. Shingles Vaccine Market: Product Estimates & Trend Analysis

  • 4.1. Global Shingles Vaccine Market: Product Dashboard
  • 4.2. Global Shingles Vaccine Market: Product Movement Analysis
  • 4.3. Global Shingles Vaccine Market by Product, Revenue
  • 4.4. Shingrix
    • 4.4.1. Shingrix market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Zostavax
    • 4.5.1. Zostavax market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. SKYZoster
    • 4.6.1. SKYZoster market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Shingles Vaccine Market: Type Estimates & Trend Analysis

  • 5.1. Global Shingles Vaccine Market: Type Dashboard
  • 5.2. Global Shingles Vaccine Market: Type Movement Analysis
  • 5.3. Global Shingles Vaccine Market Estimates and Forecasts, By Type, Revenue (USD Million)
  • 5.4. Recombinant Vaccine
    • 5.4.1. Recombinant Vaccine market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Live Attenuated Vaccine
    • 5.5.1. Live Attenuated Vaccine market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Shingles Vaccine Market: End Use Estimates & Trend Analysis

  • 6.1. Global Shingles Vaccine Market: End Use Dashboard
  • 6.2. Global Shingles Vaccine Market: End Use Movement Analysis
  • 6.3. Global Shingles Vaccine Market Estimates and Forecasts, by End Use, Revenue (USD Million)
  • 6.4. Private Healthcare Settings
    • 6.4.1. Private Healthcare Settings market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Government Healthcare Settings
    • 6.5.1. Government Healthcare Settings market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Shingles Vaccine Market: Regional Estimates & Trend Analysis by Product, Type, End Use

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Vendor Landscape
    • 8.2.1. List of key distributors and channel partners
    • 8.2.2. Key customers
    • 8.2.3. Key company market share analysis, 2023
    • 8.2.4. GlaxoSmithKline plc.
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Merck & Co., Inc.
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. SK chemicals
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Green Cross Corp
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Geneone Life Science
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Vaccitech
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. CanSinoBIO
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives